Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average ...

Share on Pinterest A Wegovy weight loss pill from Novo Nordisk is forthcoming, providing an alternative to injectable GLP-1 drugs. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images Federal ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

WHITE HALL, Ark. (KATV) — White Hall High School has its new boys' head basketball coach. Trey Lenox, a 2016 graduate of Hot Springs High School and 2020 graduate of Abilene Christian University ...

Zepbound helped patients lose 50 pounds, compared to 33 pounds with Wegovy The study showed Zepbound users lost 20% of body weight Both drugs caused some mild stomach-related side effects MONDAY ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

How Much Does Wegovy Cost With and Without Insurance? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration ...

JEFFERSON COUNTY, Ark (KATV) — A missing child was reported in the Pine Bluff and White Hall areas of Jefferson County on Sunday morning. According to information provided by the Morgan Nick ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025.